ZA201704912B - Cytomegalovirus antigens and uses thereof - Google Patents
Cytomegalovirus antigens and uses thereofInfo
- Publication number
- ZA201704912B ZA201704912B ZA2017/04912A ZA201704912A ZA201704912B ZA 201704912 B ZA201704912 B ZA 201704912B ZA 2017/04912 A ZA2017/04912 A ZA 2017/04912A ZA 201704912 A ZA201704912 A ZA 201704912A ZA 201704912 B ZA201704912 B ZA 201704912B
- Authority
- ZA
- South Africa
- Prior art keywords
- cytomegalovirus antigens
- cytomegalovirus
- antigens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152221.6A EP3048114A1 (en) | 2015-01-22 | 2015-01-22 | Cytomegalovirus antigens and uses thereof |
| PCT/IB2016/050335 WO2016116904A1 (en) | 2015-01-22 | 2016-01-22 | Cytomegalovirus antigens and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201704912B true ZA201704912B (en) | 2018-12-19 |
Family
ID=52434568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/04912A ZA201704912B (en) | 2015-01-22 | 2017-07-19 | Cytomegalovirus antigens and uses thereof |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10167321B2 (https=) |
| EP (3) | EP3048114A1 (https=) |
| JP (1) | JP6717836B2 (https=) |
| KR (1) | KR20170100039A (https=) |
| CN (1) | CN107531761B (https=) |
| AU (2) | AU2016210548B2 (https=) |
| BE (1) | BE1023087B1 (https=) |
| BR (1) | BR112017015567A2 (https=) |
| CA (1) | CA2974041C (https=) |
| DK (1) | DK3247722T5 (https=) |
| EA (1) | EA038250B1 (https=) |
| ES (1) | ES2937959T3 (https=) |
| FI (1) | FI3247722T3 (https=) |
| HR (1) | HRP20230177T1 (https=) |
| HU (1) | HUE061175T2 (https=) |
| IL (1) | IL253366B (https=) |
| LT (1) | LT3247722T (https=) |
| MX (1) | MX382518B (https=) |
| PL (1) | PL3247722T3 (https=) |
| PT (1) | PT3247722T (https=) |
| SG (1) | SG11201705740UA (https=) |
| SI (1) | SI3247722T1 (https=) |
| WO (1) | WO2016116904A1 (https=) |
| ZA (1) | ZA201704912B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3351636T (pt) * | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR102403547B1 (ko) | 2014-07-16 | 2022-05-30 | 오레곤 헬스 앤드 사이언스 유니버시티 | 외인성 항원을 포함하는 인간 시토메갈로바이러스 |
| JP6816031B2 (ja) | 2015-02-10 | 2021-01-20 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| EP3324979B1 (en) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Infectious disease vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| AU2016355468B2 (en) | 2015-11-20 | 2022-12-15 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| US11246920B2 (en) | 2016-03-03 | 2022-02-15 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| EP3519428A4 (en) | 2016-10-03 | 2020-07-08 | Duke University | METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS |
| CN110036112B (zh) | 2016-10-18 | 2024-05-10 | 俄勒冈健康与科学大学 | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| WO2018151816A1 (en) | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
| CA3060019A1 (en) * | 2017-04-19 | 2018-10-25 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| US11773144B2 (en) | 2017-10-02 | 2023-10-03 | Duke University | Mosaic HIV-1 envelopes to induce ADCC responses |
| CA3095216A1 (en) | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| US12138304B2 (en) | 2018-10-01 | 2024-11-12 | Duke University | HIV-1 envelope stabilizing mutations |
| CA3116175A1 (en) | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| CN109627330A (zh) * | 2018-12-18 | 2019-04-16 | 马鞍山史记动物健康管理有限公司 | 一种猪伪狂犬病毒高效价阳性血清制备方法 |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| EP4004018A1 (en) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
| TWI810589B (zh) * | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20250101067A1 (en) | 2022-01-28 | 2025-03-27 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| CN118480118B (zh) * | 2022-10-21 | 2025-08-19 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE174058T1 (de) | 1989-11-06 | 1998-12-15 | Cell Genesys Inc | Herstellung von proteinen mittels homologer rekombination |
| EP3031469B1 (en) | 2006-06-07 | 2023-08-23 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| PE20141435A1 (es) * | 2008-07-16 | 2014-10-22 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| EP2590625B1 (en) | 2010-07-06 | 2017-09-20 | GlaxoSmithKline Biologicals SA | Cationic oil-in-water emulsions |
| JP2013544504A (ja) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
| CA2840965C (en) | 2011-07-06 | 2021-03-02 | Novartis Ag | Cationic oil-in-water emulsions |
| TWI570240B (zh) * | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ |
| ES2753138T3 (es) | 2012-07-06 | 2020-04-07 | Glaxosmithkline Biologicals Sa | Complejos de proteínas de citomegalovirus |
| MX2015005505A (es) * | 2012-10-30 | 2016-01-08 | Redvax Gmbh | Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano. |
| ES2758505T3 (es) | 2013-12-20 | 2020-05-05 | Novartis Ag | Células eucariotas novedosas y métodos para expresar de forma recombinante un producto de interés |
| WO2015092735A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Novel eukaryotic cells and methods for recombinantly expressing a product of interest |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP3047856A1 (en) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
-
2015
- 2015-01-22 EP EP15152221.6A patent/EP3048114A1/en not_active Withdrawn
-
2016
- 2016-01-22 CN CN201680017610.XA patent/CN107531761B/zh active Active
- 2016-01-22 DK DK16702210.2T patent/DK3247722T5/da active
- 2016-01-22 AU AU2016210548A patent/AU2016210548B2/en not_active Ceased
- 2016-01-22 HU HUE16702210A patent/HUE061175T2/hu unknown
- 2016-01-22 WO PCT/IB2016/050335 patent/WO2016116904A1/en not_active Ceased
- 2016-01-22 FI FIEP16702210.2T patent/FI3247722T3/fi active
- 2016-01-22 ES ES16702210T patent/ES2937959T3/es active Active
- 2016-01-22 SG SG11201705740UA patent/SG11201705740UA/en unknown
- 2016-01-22 JP JP2017538387A patent/JP6717836B2/ja active Active
- 2016-01-22 PT PT167022102T patent/PT3247722T/pt unknown
- 2016-01-22 HR HRP20230177TT patent/HRP20230177T1/hr unknown
- 2016-01-22 BR BR112017015567A patent/BR112017015567A2/pt not_active Application Discontinuation
- 2016-01-22 SI SI201631665T patent/SI3247722T1/sl unknown
- 2016-01-22 BE BE2016/5050A patent/BE1023087B1/fr not_active IP Right Cessation
- 2016-01-22 EA EA201791562A patent/EA038250B1/ru unknown
- 2016-01-22 EP EP22203406.8A patent/EP4180056A1/en active Pending
- 2016-01-22 KR KR1020177023123A patent/KR20170100039A/ko not_active Ceased
- 2016-01-22 PL PL16702210.2T patent/PL3247722T3/pl unknown
- 2016-01-22 CA CA2974041A patent/CA2974041C/en active Active
- 2016-01-22 MX MX2017009538A patent/MX382518B/es unknown
- 2016-01-22 EP EP16702210.2A patent/EP3247722B1/en active Active
- 2016-01-22 LT LTEPPCT/IB2016/050335T patent/LT3247722T/lt unknown
- 2016-01-22 US US15/544,730 patent/US10167321B2/en active Active
-
2017
- 2017-07-09 IL IL253366A patent/IL253366B/en unknown
- 2017-07-19 ZA ZA2017/04912A patent/ZA201704912B/en unknown
-
2018
- 2018-09-10 AU AU2018226521A patent/AU2018226521B2/en not_active Ceased
- 2018-11-15 US US16/192,347 patent/US20190276498A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283321A (en) | Antibodies against muc16 and their uses | |
| ZA201704912B (en) | Cytomegalovirus antigens and uses thereof | |
| IL258284A (en) | Anti-Lag 3 antibodies and their uses | |
| IL257263A (en) | Antibodies against angptl8 and their use | |
| ZA201800536B (en) | Il-8-binding antibodies and uses thereof | |
| IL252804B (en) | Anti-c10orf54 antibodies and their use | |
| IL251248A0 (en) | Anti-interleukin-33 antibodies and their uses | |
| IL254954B (en) | Anti-pacap antibodies and their uses | |
| ZA201605894B (en) | Anti-egfrviii antibodies and uses thereof | |
| GB201403875D0 (en) | Novel antibodies and uses thereof | |
| GB201413913D0 (en) | Novel antibodies and uses thereof | |
| ZA201701663B (en) | Anti-il-25 antibodies and uses thereof | |
| PL3292154T3 (pl) | Przeciwciała przeciwko ludzkiemu HER3 i ich zastosowania | |
| GB201503387D0 (en) | Anti-carbapenem antibodies and uses thereof |